Enhancing Patient Experience in Geriatric Oncology
Enhancing the Experience of Older Adults With Cancer Through a Comfort Menu and Cart for: Protocol of a Quasi-experimental, Before-and-after Study in a Tertiary Oncology Center
Approximately 60% of new cancer diagnoses and 70% of cancer-related deaths occur in adults aged 65 years and older, a population frequently affected by multimorbidity, frailty, sensory impairment, and treatment-related symptom burden. Outpatient oncology centers, although designed for efficient antineoplastic therapy delivery, are rarely adapted to the specific needs of older adults, and pragmatic, low-cost interventions to enhance patient experience and the clinical care journey remain scarce. The "comfort menu and cart," a non-pharmacological strategy initially developed for the emergency department, has shown promising effects on patient and staff experience, but has not been evaluated in the geriatric oncology setting.
Methods: This protocol describes a quasi-experimental, before-and-after, single-center study evaluating the implementation of a comfort menu and cart at the Oncology Center of Hospital Sírio-Libanês, a tertiary philanthropic hospital in São Paulo, Brazil. Patients aged 65 years and older receiving intravenous chemotherapy, supportive therapy, or evaluation of intercurrent symptoms during oncological treatment will be recruited over 12 months: six months pre-intervention and six months post-intervention, with 132 participants per phase and a total sample of 264 participants. All participants will undergo a comprehensive geriatric assessment, including G8, Charlson Comorbidity Index, Clinical Frailty Scale, Geriatric Depression Scale - 15-item version, Katz Index of Independence in Activities of Daily Living, Barthel Index of Activities of Daily Living, Lawton-Brody Instrumental Activities of Daily Living Scale, 10-point Cognitive Screener, and EuroQol 5-Dimension questionnaire. This assessment will be complemented by oncology-specific patient-reported outcomes, including the Edmonton Symptom Assessment System, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information 25, and a structured adherence questionnaire. Caregiver anxiety, depression, and burden will be assessed using the Hospital Anxiety and Depression Scale and the Zarit Burden Interview short version. The primary outcome will be patient experience, measured using Likert-scale instruments adapted from previously published comfort care and emergency department experience instruments. Secondary outcomes include staff experience, length of stay, satisfaction indicators, oncological treatment adherence, symptom control, patient understanding of disease-related information, functionality, need for re-evaluation, hospital admissions, and caregiver outcomes at 30 days.
Expected Results: The study is expected to demonstrate that a low-cost, non-pharmacological intervention can enhance the experience of older adults with cancer and multidisciplinary teams, with favorable effects on symptom control, information comprehension, treatment adherence, and 30-day clinical outcomes.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Theodora Karnakis, MD, PhD
- Telefonnummer: 055 11 984957475
- E-Mail: theokarnakis@gmail.com
Studieren Sie die Kontaktsicherung
- Name: Theodora Karnakis, Md, PhD
- Telefonnummer: 5511984957475
- E-Mail: theokarnakis@gmail.com
Studienorte
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01308050
- Hospital Sirio Libanes
-
Kontakt:
- Theodora Karnakis, MD, PhD
- Telefonnummer: +55 11 942025633
- E-Mail: theokarnakis@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age 60 years or older.
- Receiving care at the Oncology Center in the context of active cancer treatment: intravenous chemotherapy, supportive therapy, or clinical evaluation.
- Capacity to provide informed consent and respond to the interview, or presence of a legal representative or companion able to do so.
Exclusion criteria.
- Refusal to participate in the study or to use the comfort menu and cart items.
- Decreased level of consciousness or acute clinical instability (hemodynamic instability, acute respiratory failure).
- Absence of a companion able to consent and provide information when the patient presents cognitive impairment.
- Inability to be contacted by telephone for the follow-up interview.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Pré - Intervention
Usual Oncologic Care
|
|
|
Experimental: Post - Intervention
Comfort menu and cart implemented
|
The comfort menu and cart will be implemented after the pre-intervention data collection phase.The cart will be positioned in an easily accessible area of the infusion floor, and the menu will be presented to eligible patients in printed or digital format (tablet). A one-month rollout period will precede post-intervention enrolment, dedicated to staff training and resolution of logistic challenges, in order to optimize fidelity. Comfort cart contents: Hot and cold packs; Extra blankets and pillows; face towels; gloves and hats; Personal hygiene kit (toothbrush, toothpaste, cotton swabs, sleep mask, comb, deodorant, hand lotion); Distraction items (magazines, word-search puzzles, playing cards, coloring pages); Communication and orientation aids (reading glasses, magnifying glass, penlight, mobile phone charger, notepad, sound amplification device). Comfort menu options (oncology-specific): Physiotherapy assessment;Conversation with chaplain, concierge, or social worker. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Experience of older patients treated in the tertiary oncology center
Zeitfenster: Baseline assessment during oncologic center stay
|
Patient experience will be assessed using the Older Adult Oncology Patient Experience Scale, composed by Likert scale items. measured by Likert-scale items, assess perceived comfort, age-specific care, communication, and respect during the index oncology center visit. Each item is scored on a 5-point LIKERT SCALE ranging 1 to 5, whwrw 1 indicates the least fevorable experience and 5 indicates the most favorable experience. Higher scores indicate a better patient experience. In the post - intervention phase, assitional items will assess use of, and perceived value atributed, the comfort card and comfort menu. These items will also be scored on the same 5-point Likert scale randging 1 to 5, with higher scores indicating greater perceived values or satisfaction |
Baseline assessment during oncologic center stay
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Experience of medical and multidisciplinary staff involved in caring for older patients treated in the oncologic Center
Zeitfenster: 6 months pre and post intervention, cuncurrent with patients inclusion
|
The interview will fololow the standartization of the original comfort cart validation study, using the Older Adult Oncology Patient Experience Scale, composed by Likert scale items. measured by Likert-scale items, assess perceived comfort, age-specific care, communication, and respect during the index oncology center visit. Each item is scored on a 5-point LIKERT SCALE ranging 1 to 5, whwrw 1 indicates the least fevorable experience and 5 indicates the most favorable experience. Higher scores indicate a better patient experience. In the post - intervention phase, assitional items will assess use of, and perceived value atributed, the comfort card and comfort menu. These items will also be scored on the same 5-point Likert scale randging 1 to 5, with higher scores indicating greater perceived values or satisfaction. |
6 months pre and post intervention, cuncurrent with patients inclusion
|
|
Transactional Net Promoter Score
Zeitfenster: 30 days
|
Institutional satisfaction will be assessed using the Transactional Net Promoter Score, calculated from the standard 0-to-10 recommendation question.
Respondents scoring 9-10 will be classified as promoters, 7-8 as passives, and 0-6 as detractors.
The final Transactional Net Promoter Score ranges from -100 to +100, with higher scores indicating greater institutional satisfaction.
|
30 days
|
|
Number of Ombudsman Manifestations Classified by Type
Zeitfenster: 30 days
|
Ombudsman manifestations related to the intervention period will be classified as complaints, suggestions, or compliments.
The outcome will be reported as the number of manifestations in each category during the 30-day assessment period.
|
30 days
|
|
Caregiver anxiety and depression symptoms
Zeitfenster: Baselina assessment during Oncologic Center stay
|
Caregiver anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS).
The HADS includes two subscales: anxiety and depression.
Each subscale ranges from 0 to 21, with higher scores indicating greater symptom severity and therefore a worse outcome.
|
Baselina assessment during Oncologic Center stay
|
|
Caregiver burden
Zeitfenster: Baseline assessement using oncologic center stay
|
Caregiver burden will be assessed using the 12-item Zarit Burden Interview Short Form (ZBI-12).
Each item is scored from 0 to 4, and the total score ranges from 0 to 48, with higher scores indicating greater caregiver burden and therefore a worse outcome.
|
Baseline assessement using oncologic center stay
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Length of Stay Beyond Programmed Duration in the Infusion Oncology Center
Zeitfenster: At discharge from the index Oncology Center visit
|
Length of stay beyond the programmed duration will be assessed during the index visit to the Infusion Oncology Center.
This outcome will be calculated as the difference between the actual time spent in the Infusion Oncology Center and the programmed duration of the visit, reported in minutes.
|
At discharge from the index Oncology Center visit
|
|
Symptom burden
Zeitfenster: At 30 days after the index Oncology Center visit
|
Symptom burden will be assessed using the Edmonton Symptom Assessment System (ESAS).
Each symptom is scored from 0 to 10, where 0 indicates absence of the symptom and 10 indicates the worst possible symptom severity.
The total ESAS symptom burden score will be calculated as the sum of the assessed symptom items, ranging from 0 to 90, with higher scores indicating greater symptom burden and therefore a worse outcome.
|
At 30 days after the index Oncology Center visit
|
|
Understanding of the information received
Zeitfenster: At 30 days after the index Oncology Center visit
|
Understanding of the information received will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information 25 (EORTC QLQ-INFO25).
Scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better understanding of the information received and therefore a better outcome.
|
At 30 days after the index Oncology Center visit
|
|
Completion of Oncological Treatment as Planned
Zeitfenster: 30 days after the index Oncology Center visit
|
Oncological treatment completion will be assessed as the proportion of patients who complete the planned oncological treatment without unplanned discontinuation during the 30-day assessment period.
The outcome will be reported as the number and percentage of patients who completed treatment as planned.
|
30 days after the index Oncology Center visit
|
|
Functionality- Basic Activities of Daily Living Assessed by the Katz Index
Zeitfenster: At 30 days after the index Oncology Center visit
|
Basic activities of daily living will be assessed using the Katz Index of Independence in Activities of Daily Living.
The total score ranges from 0 to 6, with higher scores indicating greater functional independence and therefore a better outcome.
|
At 30 days after the index Oncology Center visit
|
|
Functionality- Basic Activities of Daily Living Assessed by the Barthel Index
Zeitfenster: At 30 days after the index Oncology Center visit
|
Basic activities of daily living will be assessed using the Barthel Index of Activities of Daily Living.
The total score ranges from 0 to 100, with higher scores indicating greater functional independence and therefore a better outcome.
|
At 30 days after the index Oncology Center visit
|
|
Functionality - Instrumenctal activities of daily living
Zeitfenster: At 30 days after the index Oncology Center visit
|
Instrumental activities of daily living will be assessed using the Lawton-Brody Instrumental Activities of Daily Living Scale.
In the version used in this study, total scores range from 9 to 27, with higher scores indicating better functionality and less dependence, from total dependence to mild dependence.
|
At 30 days after the index Oncology Center visit
|
|
Cognitive performance
Zeitfenster: At 30 days after the index Oncology Center visit
|
Adressed using the 10 point cognitive screener.
With a score ranging from 0 to 10, it classifies cognitive performance as normal ( > = 8) , possible cognitive impeirement (6-7), or probaple cognitive imeirement (0-5), with adjustments for education level.
|
At 30 days after the index Oncology Center visit
|
|
Mood symptom
Zeitfenster: At 30 days after the index Oncology Center visit
|
Mood symptoms will be assessed using the Geriatric Depression Scale - 15-item version (GDS-15).
The total score ranges from 0 to 15, with higher scores indicating more depressive symptoms and therefore a worse outcome.
|
At 30 days after the index Oncology Center visit
|
|
Clinical re-evaluations and unplanned hospital admissions
Zeitfenster: At 30 days after the index Oncology Center visit
|
Number of clinical re-evaluations and unplanned hospital admissions in the 30 days following the index visit.
|
At 30 days after the index Oncology Center visit
|
|
Falls
Zeitfenster: At 30 days after the index Oncology Center visit
|
number of falls at 30 days.
|
At 30 days after the index Oncology Center visit
|
|
Mortality
Zeitfenster: At 30 days after the index Oncology Center visit
|
Mortality at 30 days.
|
At 30 days after the index Oncology Center visit
|
|
Dose Reduction Due to Toxicity
Zeitfenster: 30 days after the index Oncology Center visit
|
Dose reduction due to toxicity will be assessed as the proportion of patients who require any reduction in the planned oncological treatment dose because of treatment-related toxicity during the 30-day assessment period.
The outcome will be reported as the number and percentage of patients with dose reduction due to toxicity.
|
30 days after the index Oncology Center visit
|
|
Treatment Delay or Interruption Due to Toxicity
Zeitfenster: 30 days after the index Oncology Center visit
|
Treatment delay or interruption due to toxicity will be assessed as the proportion of patients who experience any delay or interruption of oncological treatment because of treatment-related toxicity during the 30-day assessment period.
The outcome will be reported as the number and percentage of patients with treatment delay or interruption due to toxicity.
|
30 days after the index Oncology Center visit
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Theodora Karnakis, MD, PhD, Hospital Sírio-Libanês
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- AVAP-NG 3776-B
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .